NASDAQ:CDXS Codexis (CDXS) Stock Price, News & Analysis $1.15 +0.08 (+7.48%) As of 11/18/2026 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Codexis Stock (NASDAQ:CDXS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Codexis alerts:Sign Up Key Stats Today's Range$1.06▼$1.1850-Day Range$0.96▼$1.4852-Week Range$0.90▼$2.98Volume1.47 million shsAverage Volume950,720 shsMarket Capitalization$126.04 millionP/E RatioN/ADividend YieldN/APrice Target$6.00Consensus RatingHold Company Overview Codexis, Inc. is a biotechnology company that develops engineered enzymes for pharmaceutical and other manufacturing applications. Founded in 2002 and based in Redwood City, California, the company uses its protein-engineering platform, CodeEvolver, to design enzymes with properties suited to specific production processes. Codexis supplies enzymes and related development services for the manufacture of small-molecule drugs and other products. It also develops its ECO Synthesis platform, which uses enzymes to support the production of oligonucleotide therapeutics, including RNA-based medicines. The company works with pharmaceutical and biotechnology partners to develop and apply its technologies in manufacturing. Its business centers on improving production processes through enzyme engineering and biocatalysis.AI Generated. May Contain Errors. Read More Codexis Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks64th Percentile Overall ScoreCDXS MarketRank™: 3.221568359105 of 5 starsCodexis scored higher than 64% of companies evaluated by MarketBeat, and ranked 449th out of 1,704 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingHold Consensus RatingCodexis has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on no strong buy ratings, 3 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialCodexis has a consensus price target of $6.00, representing about 421.7% upside from its current price of $1.15.Amount of Analyst CoverageCodexis has only been the subject of 2 research reports in the past 90 days.Read more about Codexis' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Codexis are expected to grow in the coming year, from ($0.37) to ($0.25) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Codexis is -5.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Codexis is -5.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCodexis has a P/B Ratio of 2.45. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.16% of the float of Codexis has been sold short.Short Interest Ratio / Days to CoverCodexis has a short interest ratio ("days to cover") of 4.89.Change versus previous monthShort interest in Codexis has recently decreased by 11.20%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCodexis does not currently pay a dividend.Dividend GrowthCodexis does not have a long track record of dividend growth. News and Social Media2.7 / 5News Sentiment0.38 News SentimentCodexis has a news sentiment score of 0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 18 news articles for Codexis this week, compared to 2 articles on an average week.Search Interest3 people have searched for CDXS on MarketBeat in the last 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Codexis insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $29,373.00 in company stock.Percentage Held by Insiders3.50% of the stock of Codexis is held by insiders.Percentage Held by Institutions78.54% of the stock of Codexis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Codexis' insider trading history. Receive CDXS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Codexis and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CDXS Stock News HeadlinesCodexis (NASDAQ:CDXS) CEO Alison Moore Sells 10,651 Shares of Stock1 hour ago | insidertrades.comCodexis to Participate in Piper Sandler 38th Annual Healthcare Conference3 hours ago | globenewswire.comI'm handing you this stock todayElon doesn't own the chip inside his Teslas or Starlink dishes. He licenses it from one little known public company. Now he's planning 1,000,000 AI satellites in orbit, and every one could pay this company a royalty. Analyst Dylan says the window to get in closes around December 8th, before new money floods into the buildout.November 19 at 1:00 AM | Behind the Markets (Ad)Codexis, Inc. (CDXS)November 18 at 8:45 AM | finance.yahoo.comCodexis (NASDAQ:CDXS) Earns Overweight Rating from StephensNovember 18 at 1:18 AM | americanbankingnews.comCodexis (NASDAQ:CDXS) Upgraded at Wall Street ZenNovember 17 at 3:19 AM | americanbankingnews.comCodexis (CDXS) Q3 2026 Earnings Call TranscriptNovember 13, 2026 | finance.yahoo.comCodexis, Inc. (CDXS) Q3 2026 Earnings Call TranscriptNovember 12, 2026 | seekingalpha.comSee More Headlines CDXS Stock Analysis - Frequently Asked Questions How have CDXS shares performed this year? Codexis' stock was trading at $1.63 at the beginning of 2026. Since then, CDXS stock has decreased by 29.4% and is now trading at $1.15. How were Codexis' earnings last quarter? Codexis, Inc. (NASDAQ:CDXS) posted its earnings results on Thursday, November, 12th. The biotechnology company reported ($0.08) EPS for the quarter, topping analysts' consensus estimates of ($0.10) by $0.02. The biotechnology company had revenue of $19.26 million for the quarter, compared to analysts' expectations of $18.72 million. Codexis had a negative trailing twelve-month return on equity of 43.24% and a negative net margin of 21.77%. Read the conference call transcript. When did Codexis IPO? Codexis (CDXS) raised $0 in an initial public offering on Thursday, April 22nd 2010. The company issued 0 shares at a price of $0.00-$13.00 per share. Who are Codexis' major shareholders? Top institutional shareholders of Codexis include Aberdeen Group plc (9.86%), Nantahala Capital Management LLC (2.37%), State Street Corp (1.49%) and Private Advisor Group LLC (1.10%). Insiders that own company stock include Opaleye Management Inc, Alison Moore, Stefan Lutz, Vre Raymond De and Georgia Erbez. View institutional ownership trends. How do I buy shares of Codexis? Shares of CDXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Codexis own? Based on aggregate information from My MarketBeat watchlists, some other companies that Codexis investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), Micron Technology (MU), NIO (NIO), Tesla (TSLA), CRISPR Therapeutics (CRSP) and Cisco Systems (CSCO). Company Calendar Last Earnings11/12/2026Today11/19/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (2w+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 For the last 2 weeks, CDXS's financial health has been in the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Life Sciences Tools & Services Sub-IndustryLife Sciences Tools & Services Current SymbolNASDAQ:CDXS CIK1200375 Webwww.codexis.com Phone(650) 421-8100Fax650-421-8102Employees146Year Founded2002Price Target and Rating Average Price Target for Codexis$6.00 High Price Target$8.00 Low Price Target$5.00 Potential Upside/Downside+421.7%Consensus RatingHold Rating Score (0-4)2.40 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($0.20) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$43.97 million Net Margins-21.77% Pretax Margin-21.69% Return on Equity-43.24% Return on Assets-14.21% Debt Debt-to-Equity Ratio0.58 Current Ratio2.81 Quick Ratio2.99 Sales & Book Value Annual Sales$88.34 million Price / Sales1.43 Cash FlowN/A Price / Cash FlowN/A Book Value$0.47 per share Price / Book2.45Miscellaneous Outstanding Shares109,598,000Free Float105,762,000Market Cap$126.04 million OptionableOptionable Beta2.38 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NASDAQ:CDXS) was last updated on 11/18/2026 by MarketBeat.com Staff. From Our PartnersChase, Wells Fargo and Capital One all showed errors on Nov. 16On November 16, customers of Chase, Bank of America, Wells Fargo, Capital One and Zelle reported errors when t...Cedar Gold Group | SponsoredYour $7 scanner is waitingThe Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which sto...Profits Run | SponsoredPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredThe Democrats can’t stop thisPorter Stansberry believes President Trump has begun a full dollar reset through executive order 14241, bypass...Porter & Company | SponsoredTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour father's savings lost half their value after 1971.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredA Bill Would Reprice America's Gold at Market ValueThe US government still values its gold at $42 an ounce, a price Congress set in 1973. Gold trades above $4,00...Concord Gold Capital | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Codexis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Codexis With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.